NASDAQ:SESN - Sesen Bio Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.23 +0.10 (+8.85 %) (As of 12/19/2018 10:31 AM ET)Previous Close$1.13Today's Range$1.15 - $1.2452-Week Range$0.68 - $3.50Volume9,700 shsAverage Volume1.08 million shsMarket Capitalization$101.47 millionP/E Ratio-1.10Dividend YieldN/ABeta2.9 ProfileDiscussionAnalyst RatingsChartEarningsInstitutional OwnershipHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts. Receive SESN News and Ratings via Email Sign-up to receive the latest news and ratings for SESN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SESN Previous Symbol CUSIPN/A Webwww.sesenbio.com Phone617-444-8550 Debt Debt-to-Equity RatioN/A Current Ratio9.05 Quick Ratio9.05 Price-To-Earnings Trailing P/E Ratio-1.10 Forward P/E Ratio-2.28 P/E GrowthN/A Sales & Book Value Annual Sales$430,000.00 Price / Sales221.57 Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book2.16 Profitability EPS (Most Recent Fiscal Year)($1.11) Net Income$-29,020,000.00 Net MarginsN/A Return on Equity-85.67% Return on Assets-33.62% Miscellaneous Employees17 Outstanding Shares77,460,000Market Cap$101.47 million OptionableOptionable Sesen Bio (NASDAQ:SESN) Frequently Asked Questions What is Sesen Bio's stock symbol? Sesen Bio trades on the NASDAQ under the ticker symbol "SESN." How were Sesen Bio's earnings last quarter? Sesen Bio Inc (NASDAQ:SESN) announced its quarterly earnings data on Thursday, November, 8th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.08. View Sesen Bio's Earnings History. When is Sesen Bio's next earnings date? Sesen Bio is scheduled to release their next quarterly earnings announcement on Wednesday, April 3rd 2019. View Earnings Estimates for Sesen Bio. What price target have analysts set for SESN? 3 brokers have issued 12-month price targets for Sesen Bio's shares. Their forecasts range from $3.00 to $4.00. On average, they expect Sesen Bio's stock price to reach $3.50 in the next year. This suggests a possible upside of 184.6% from the stock's current price. View Analyst Price Targets for Sesen Bio. What is the consensus analysts' recommendation for Sesen Bio? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sesen Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sesen Bio. Has Sesen Bio been receiving favorable news coverage? News articles about SESN stock have been trending positive this week, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sesen Bio earned a coverage optimism score of 3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the near term. Who are some of Sesen Bio's key competitors? Some companies that are related to Sesen Bio include Akebia Therapeutics (AKBA), Synthorx (THOR), Sinovac Biotech (SVA), Cytokinetics (CYTK), Odonate Therapeutics (ODT), ZEALAND PHARMA/S (ZEAL), Kindred Biosciences (KIN), ZIOPHARM Oncology (ZIOP), MediciNova (MNOV), Progenics Pharmaceuticals (PGNX), Evelo Biosciences (EVLO), TG Therapeutics (TGTX), Clementia Pharmaceuticals (CMTA), Corbus Pharmaceuticals (CRBP) and ArQule (ARQL). Who are Sesen Bio's key executives? Sesen Bio's management team includes the folowing people: Mr. Richard F. Fitzgerald, CFO, Sec. & Treasurer (Age 54)Dr. Thomas R. Cannell, Pres, CEO & Director (Age 56)Dr. K. Christopher Garcia, Co-Founder & Member of Scientific Advisory BoardDr. Gregory L. Verdine, Co-Founder (Age 59)Dr. Casey T. Weaver, Co-Founder & Member of Scientific Advisory Board Who are Sesen Bio's major shareholders? Sesen Bio's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc (3.25%), Vanguard Group Inc. (3.25%), BlackRock Inc. (1.83%), Nexthera Capital LP (1.53%), Sphera Funds Management LTD. (0.82%) and Dimensional Fund Advisors LP (0.23%). Which major investors are selling Sesen Bio stock? SESN stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD.. Which major investors are buying Sesen Bio stock? SESN stock was purchased by a variety of institutional investors in the last quarter, including Nexthera Capital LP, Vanguard Group Inc, Vanguard Group Inc., Dimensional Fund Advisors LP, Bridgeway Capital Management Inc., BlackRock Inc. and Hikari Power Ltd. How do I buy shares of Sesen Bio? Shares of SESN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Sesen Bio's stock price today? One share of SESN stock can currently be purchased for approximately $1.23. How big of a company is Sesen Bio? Sesen Bio has a market capitalization of $101.47 million and generates $430,000.00 in revenue each year. The company earns $-29,020,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. Sesen Bio employs 17 workers across the globe. What is Sesen Bio's official website? The official website for Sesen Bio is http://www.sesenbio.com. How can I contact Sesen Bio? Sesen Bio's mailing address is 245 FIRST STREET SUITE 1800, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-444-8550 or via email at [email protected] MarketBeat Community Rating for Sesen Bio (NASDAQ SESN)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 34 (Vote Outperform)Underperform Votes: 20 (Vote Underperform)Total Votes: 54MarketBeat's community ratings are surveys of what our community members think about Sesen Bio and other stocks. Vote "Outperform" if you believe SESN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SESN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/19/2018 by MarketBeat.com StaffFeatured Article: What is a Fiduciary?